Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

6(66.7%)

Phase 4

3(33.3%)

9Total

N/A(6)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02528604Phase 4Completed

Electrical Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation

Role: lead

NCT02506621Not ApplicableUnknown

ELR Monitoring Against Permanent Pacemaker in Atrial Fibrillation

Role: lead

NCT02388087Not ApplicableUnknown

The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study

Role: lead

NCT02016950Completed

Long-term Pacemaker Arrhythmia Analysis

Role: lead

NCT01503268Phase 4Withdrawn

Atrial Fibrillation After Catheter Versus Thoracoscopic Ablation Using Patient Activated Implantable Loop Recorders: The ACTUAL Study

Role: lead

NCT01266681Not ApplicableUnknown

Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm

Role: lead

NCT01057485Not ApplicableUnknown

Node and Atrial Fibrillation Ablation for Persistent Atrial Fibrillation

Role: lead

NCT01095770Not ApplicableUnknown

Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP

Role: lead

NCT01070667Phase 4Unknown

Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation

Role: lead

NCT00517023Not ApplicableUnknown

Eastbourne Syncope Assessment Study II

Role: lead

All 10 trials loaded